You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,084,815


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,084,815
Title:Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
Abstract: Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): ##STR00001## to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: SUCAMPO AG (Zug, CH)
Application Number:12/882,794
Patent Claims:1. A method for treating oral mucositis induced by an anti-tumor agent in a mammalian subject, which comprises administering a pharmaceutically effective amount of (-)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-o- xooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid to the subject in need thereof, wherein the subject is receiving the anti-tumor agent that is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic, a plant alkaloid, a molecular targeting drug, a hormone, a platinum complex, an antisense, an antibody and RNAi, wherein the molecular targeting drug is selected from the group consisting of imatinib, gefinitib, erlotinib, sorafenib, sunitinib, trastuzumab, rituximab, gemtuzumab-ozogamicin, bevacizumab and cetuximab, the hormone is selected from group consisting of prednisolone, diethylstilbestrol and tamoxifen, the antisense is selected from the group consisting of bcl-2 antisense, hsp27 antisense, XIAP antisense, PKC-alpha antisense and hypoxia-induced factor antisense, the antibody is selected from the group consisting of CD20 antibody, Her2 antibody, VEGF antibody and EGFR antibody, and the RNAi is RNAi targeted Ribonucleotide reductase.

2. The method as described in claim 1, wherein said anti-tumor agent is 5-FU or tegafur.

3. The method as described in claim 1, wherein said anti-tumor agent is cisplatin.

4. The method as described in claim 1, wherein the oral mucositis is stomatitis.

5. The method as described in claim 1, wherein the anti-tumor agent is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic and a plant alkaloid.

Details for Patent 9,084,815

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2029-09-16
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2029-09-16
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-09-16
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2029-09-16
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2029-09-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.